

**THE UNITED STATES PATENT AND TRADEMARK OFFICE**

1fw

Applicant: Ning Hu et al.

Title: METHOD OF DRUG LOADING IN LIPOSOMES BY GRADIENT

Docket No.: 1992.007US1

Serial No.: 10/723,431

Filed: November 26, 2003

Due Date: N/A

Examiner: Unknown

Group Art Unit: 1615

**Mail Stop Amendment**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

We are transmitting herewith the following attached items (as indicated with an "X"):

- ☒ A return postcard.
- ☒ A Communication Concerning Related Applications (1 pg.).
- ☒ An Information Disclosure Statement (2 pgs.), Form 1449 (4 pgs.), and copies of 41 cited documents.
- ☒ Copy of International Search Report from Corresponding Foreign Application No. PCT/US 03/37964 (11 pgs.).

Please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.


Customer Number 21186

By: 

Atty: Gary J. Speier

Reg. No. 45,458

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 9 day of February, 2005.



Name



Signature

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

(GENERAL)

S/N 10/723,431

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ning Hu et al.

Examiner: Unknown

Serial No.: 10/723,431

Group Art Unit: 1615

Filed: November 26, 2003

Docket: 1992.007US1

Title: METHOD OF DRUG LOADING IN LIPOSOMES BY GRADIENT

COMMUNICATION CONCERNING RELATED APPLICATIONS

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Applicants would like to bring to the Examiner's attention the following related applications in the above-identified patent application:

| <u>Serial/Patent No.</u> | <u>Filing Date</u> | <u>Attorney Docket</u> | <u>Title</u>           |
|--------------------------|--------------------|------------------------|------------------------|
| 10/723,423               | November 26, 2003  | 1992.005US1            | LIPOSOMAL FORMULATIONS |

Respectfully submitted,

NING HU ET AL.

By Applicants' Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.  
P.O. Box 2938  
Minneapolis, MN 55402  
(612) 359-3261

Date

2/7/05

By

Gary J. Speier

Reg. No. 45,458

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 9 day of February, 2005.

Name

Ning Hu

Signature

[Signature]

S/N 10/723,431

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ning Hu et al.

Examiner: Unknown

Serial No.: 10/723,431

Group Art Unit: 1615

Filed: November 26, 2003

Docket: 1992.007US1

Title: METHOD OF DRUG LOADING IN LIPOSOMES BY GRADIENT

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Information Disclosure Statement considered.

INFORMATION DISCLOSURE STATEMENT

Serial No :10/723,431

Filing Date: November 26, 2003

Title: METHOD OF DRUG LOADING IN LIPOSOMES BY GRADIENT

Page 2

Dkt: 1992.007US1

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Pursuant to 37 C.F.R. 1.98(a)(2), Applicant believes that copies of cited U.S. Patents and Published Applications are no longer required to be provided to the Office. Notification of this change was provided in the United States Patent and Trademark Office OG Notices dated October 12, 2004. Thus, Applicant has not included copies of any US Patents or Published Applications cited with this submission. Should the Office require copies to be provided, Applicant respectfully requests that notice of such requirement be directed to Applicant's below-signed representative. Applicant acknowledges the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2).


Respectfully submitted,  
NING HU ET AL.

By their Representatives,  
SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.  
P.O. Box 2938  
Minneapolis, MN 55402  
(612) 359-3261

Date

2/7/05


By

  
Gary J. Speier

Reg. No. 45,458

**CERTIFICATE UNDER 37 CFR 1.8:** The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 9 day of February, 2005.

Name

  
Ning Hu

Signature



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number 10/723,431

Filing Date November 26, 2003

First Named Inventor Hu, Ning

Group Art Unit 1615

Examiner Name Unknown

Attorney Docket No: 1992.007US1

Sheet 1 of 4

**US PATENT DOCUMENTS**

| Examiner Initial * | USP Document Number | Publication Date | Name of Patentee or Applicant of cited Document | Filing Date if Appropriate |
|--------------------|---------------------|------------------|---|----------------------------|
|                    | US-3,993,754        | 11/23/1976       | Rahman, Yueh-Erh , et al.                       | 10/09/1974                 |
|                    | US-4,145,410        | 03/20/1979       | Sears, Barry D.                                 | 06/17/1997                 |
|                    | US-4,224,179        | 09/23/1980       | Schneider, Michel                               | 09/23/1980                 |
|                    | US-4,235,871        | 11/25/1980       | Papahadjopoulos, Demetrios P., et al.           | 02/24/1978                 |
|                    | US-4,522,803        | 06/11/1985       | Lenk, Robert P., et al.                         | 03/24/1983                 |
|                    | US-4,588,578        | 05/13/1986       | Fountain, Michael W., et al.                    | 08/08/1983                 |
|                    | US-4,753,788        | 06/28/1988       | Gamble, Ronald C.                               | 01/31/1985                 |
|                    | US-4,885,172        | 12/05/1989       | Bally, M. B., et al.                            | 12/15/1986                 |
|                    | US-4,938,949        | 07/03/1990       | Borch, Richard F., et al.                       | 09/12/1988                 |
|                    | US-4,946,683        | 08/07/1990       | Forssen, Eric A.                                | 08/04/1989                 |
|                    | US-5,077,056        | 12/31/1991       | Bally, M. B., et al.                            | 12/12/1988                 |
|                    | US-5,316,771        | 05/31/1994       | Barenholz, Yechezkel , et al.                   | 12/18/1992                 |
|                    | US-5,380,531        | 01/10/1995       | Chakrabarti, Ajoy , et al.                      | 06/02/1992                 |
|                    | US-5,616,341        | 04/01/1997       | Mayer, L. D., et al.                            | 08/26/1993                 |
|                    | US-5,795,589        | 08/18/1998       | Mayer, Lawrence D., et al.                      | 02/05/1997                 |
|                    | US-5,814,335        | 09/29/1998       | Webb, Murray S., et al.                         | 09/17/1997                 |
|                    | US-6,083,530        | 07/04/2000       | Mayer, Lawrence D., et al.                      | 05/26/1998                 |

**FOREIGN PATENT DOCUMENTS**

| Examiner Initials* | Foreign Document No | Publication Date | Name of Patentee or Applicant of cited Document | T <sup>2</sup> |
|--------------------|---------------------|------------------|---|----------------|
|                    | EP-0290296A2        | 11/09/1988       | Bally, M. B., et al.                            |                |
|                    | EP-0546951A1        | 06/16/1993       | Ostro, Marc J.                                  |                |
|                    | EP-0719546A1        | 07/03/1996       | Bally, Marcel B., et al.                        |                |
|                    | WO-0105372A2        | 01/25/2001       | Abra, R. M., et al.                             |                |
|                    | WO-03041682A3       | 05/22/2003       | Webb, Murray , et al.                           |                |
|                    | WO-8601102A1        | 02/27/1986       | Bally, Marcel B., et al.                        |                |
|                    | WO-8700238          | 01/15/1987       | Rudham, Robert C., et al.                       |                |
|                    | WO-9202244A1        | 02/20/1992       | Chakrabarti, A. , et al.                        |                |
|                    | WO-9913816A2        | 03/25/1999       | Moynihan, Karen L., et al.                      |                |

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials* | Cite No <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|--------------------|----------------------|---|----------------|
|                    |                      | "International Search Report, for Application No. PCT/US 03/37964, date mailed July 5, 2004", 11 Pages  |                |
|                    |                      | ADLAKHA-HUTCHEON, G. , et al., "Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity", <u>Nature Biotechnology</u> , 17(8), (August 1999),775-779  |                |

**EXAMINER****DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional) <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

|                             |                   |
|-----------------------------|-------------------|
| <b>Application Number</b>   | 10/723,431        |
| <b>Filing Date</b>          | November 26, 2003 |
| <b>First Named Inventor</b> | Hu, Ning          |
| <b>Group Art Unit</b>       | 1615              |
| <b>Examiner Name</b>        | Unknown           |

Sheet 2 of 4

Attorney Docket No: 1992.007US1

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials* | Cite No <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  | T <sup>2</sup> |
|--------------------|----------------------|--|----------------|
|                    |                      | BANDAK, S. , et al., "Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models", <u>Anticancer Drugs</u> , 10, (November 10, 1999),911-920  |                |
|                    |                      | BANGHAM, A D., "Diffusion of univalent ions across the lamellae of swollen phospholipids", <u>Journal of Molecular Biology</u> , 13(1), (August 1965),238-52   |                |
|                    |                      | COLBERN, C. T., et al., "Antitumor activity of Herceptin in combination with STEALTH liposomal cisplatin or nonliposomal cisplatin in a HER2 positive human breast cancer model", <u>Journal of Inorganic Biochemistry</u> , 77(1-2), (October 1999),117-120   |                |
|                    |                      | CRAMER, J. A., "NMR Studies of pH-Induced Transport of Carboxylic Acids Across Phospholipid Vesicle Membranes", <u>Biochemical and Biophysical Research Communications</u> , 75(2), (1977),295-301   |                |
|                    |                      | DEAMER, DAVID W., et al., "Liposome Preparation: Methods and Mechanisms", Chapter 1 - In: <u>Liposomes by Marc Ostro</u> , New York : M. Dekker,(1983),27-51   |                |
|                    |                      | DEAMER, D W., et al., "The response of fluorescent amines to pH gradients across liposome membranes", <u>Biochimica et Biophysica Acta</u> , 274(2), (August 9, 1972),323-35   |                |
|                    |                      | DEMARIO, M. D., et al., "A Phase I Study of Liposome-Formulated Cisplatin (SPI-77 R) Given Every 3 Weeks in Patients With Advanced Cancer", <u>Proceedings of ASCO</u> , Vol. 17, <a href="http://www.asco.org/ac/1,1003,_12-002643-00_18-0031-00_19-006314,00.asp">http://www.asco.org/ac/1,1003,_12-002643-00_18-0031-00_19-006314,00.asp</a> ,(1998),Abstract 883 |                |
|                    |                      | FORSEN, E A., "Improved therapeutic benefits of doxorubicin by entrapment in anionic liposomes", <u>Cancer Research</u> , 43(2), (February 1983),546-50  |                |
|                    |                      | GABIZON, A , "Enhancement of adriamycin delivery to liver metastatic cells with increased tumoricidal effect using liposomes as drug carriers", <u>Cancer Research</u> , 43(10), (October 1983),4730-5   |                |
|                    |                      | GABIZON, A , "Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice", <u>Cancer Research</u> , 42(11), (November 1982),4734-9   |                |
|                    |                      | GANAPATHI, R , "Effect of cholesterol content of liposomes on the encapsulation, efflux and toxicity of adriamycin", <u>Biochem Pharmacol.</u> , 33(4), (February 15, 1984),698-700  |                |
|                    |                      | HARRINGTON, K. J., et al., "Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer", <u>Annals of Oncology</u> , 12(4), (April 2001),493-496   |                |
|                    |                      | HERMAN, E H., et al., "Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation", <u>Cancer Research</u> , 43(11), (November 1983),5427-32   |                |

**EXAMINER****DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional) <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

|                             |                   |
|-----------------------------|-------------------|
| <b>Application Number</b>   | 10/723,431        |
| <b>Filing Date</b>          | November 26, 2003 |
| <b>First Named Inventor</b> | Hu, Ning          |
| <b>Group Art Unit</b>       | 1615              |
| <b>Examiner Name</b>        | Unknown           |

Sheet 3 of 4

Attorney Docket No: 1992.007US1

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.   | T <sup>2</sup> |
|--------------------|-----------------------|---|----------------|
|                    |                       | HONG, R L., et al., "Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice is surface coating with polyethylene glycol beneficial?", <u>Clinical Cancer Research</u> , 5(11), (November 1999),3645-3652   |                |
|                    |                       | LIM, H. J., et al., "Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone", <u>The Journal of Pharmacology and Experimental Therapeutics</u> , 281(1), (April 1997),566-573  |                |
|                    |                       | LOPEZ-BERESTEIN, G , et al., "Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study", <u>The Journal of Infectious Diseases</u> , 151(4), (April 1985),704-10   |                |
|                    |                       | MEERUM TERWOGT, J. M., et al., "Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin", <u>Cancer Chemotherapy and Pharmacology</u> , 49(3), (March 2002),201-210  |                |
|                    |                       | MINOW, ROBERT A., "Adriamycin (NSC-123127) Cardiomyopathy - An Overview with Determination of Risk Factors", <u>Cancer Chemother Reports, Part 3</u> , 6(2), (October 1975),195-201   |                |
|                    |                       | NEWMAN, M. S., et al., "Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice", <u>Cancer Chemotherapy and Pharmacology</u> , 43(1), Erratum in <u>Cancer Chemotherapy and Pharmacology</u> , 43(6), 524 (attached to downloaded document),(1999),1-7 |                |
|                    |                       | OLSON, F , "Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes", <u>European Journal of Cancer &amp; Clinical Oncology</u> , 18(2), (February 1982),167-76   |                |
|                    |                       | PAPAHADJOPOULOS, D , "Phospholipid model membranes. I. Structural characteristics of hydrated liquid crystals", <u>Biochimica et Biophysica Acta</u> , 135(4), (September 9, 1967),624-638  |                |
|                    |                       | RAHMAN, A , "Doxorubicin-induced chronic cardiotoxicity and its protection by liposomal administration", <u>Cancer Research</u> , 42(5), (May 1982),1817-25   |                |
|                    |                       | RAHMAN, A , "Liposomal protection of adriamycin-induced cardiotoxicity in mice", <u>Cancer Research</u> , 40(5), (May 1980),1532-7  |                |
|                    |                       | RAHMAN, A , "Pharmacological, toxicological, and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes", <u>Cancer Research</u> , 45(2), (February 1985),796-803   |                |
|                    |                       | RICHARDSON, V , "Tissue distribution and tumour localization of 99m-technetium-labelled liposomes in cancer patients", <u>British Journal of Cancer</u> , 40(1), (July 1979),35-43  |                |
|                    |                       | ROSA, P , "Absorption and tissue distribution of doxorubicin entrapped in liposomes following intravenous or intraperitoneal administration", <u>Pharmacology</u> , 26(4), (1983),221-9   |                |

**EXAMINER****DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Applicant's unique citation designation number (optional) <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

|                             |                   |
|-----------------------------|-------------------|
| <b>Application Number</b>   | 10/723,431        |
| <b>Filing Date</b>          | November 26, 2003 |
| <b>First Named Inventor</b> | Hu, Ning          |
| <b>Group Art Unit</b>       | 1615              |
| <b>Examiner Name</b>        | Unknown           |

Sheet 4 of 4

Attorney Docket No: 1992.007US1

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

| Examiner<br>Initials* | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|-----------------------|--------------------------|---|----------------|
|                       |                          | ROSA, P. , et al., "Liposomes containg Doxorubicin - an example of drug targeting", In: <u>Transport in biomembranes : model systems and reconstitution</u> edited by Rezo Antolini, New York : Raven Press,(1982),243-256                                      |                |
|                       |                          | RYMAN, BRENDA E., et al., "Liposomes: Further Considerations of their possible role as carriers of therapeutic agents", In: <u>Targeting of drugs</u> edited by Gregory Gregoriadis, New York : Plenum Press,(1982),235-248                                     |                |
|                       |                          | SZOKA, F. , "Comparative properties and methods of preparation of lipid vesicles (liposomes).", <u>Annual Review of Biophysics and Bioengineering</u> , 9, (1980),467-508   |                |
|                       |                          | VEAL, G. J., et al., "A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin", <u>British Journal of Cancer</u> , 84(8), (April 2001),1029-1035                         |                |
|                       |                          | WORKING, P. K., et al., "Comparative intravenous toxicity of cisplatin solution and cisplatin encapsulated in long-circulating, pegylated liposomes in cynomolgus monkeys", <u>Toxicological Sciences</u> , 46(1), (November 1998),155-165                      |                |

**EXAMINER****DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional) <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached